ALSV
STOK icon

ATP Life Science Ventures’s Stoke Therapeutics STOK Stock Holding History

ATP Life Science Ventures’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,161,713
Closed -$667M – 2
2021
Q1 		$667M Hold
17,161,713
– – 74.2% 1
2020
Q4 		$1.06B Buy
17,161,713
+375,000
+2% +$17.2M 82.06% 1
2020
Q3 		$562M Hold
16,786,713
– – 75.8% 1
2020
Q2 		$392M Hold
16,786,713
– – 74.38% 1
2020
Q1 		$384M Hold
16,786,713
– – 77% 1
2019
Q4 		$475M Buy
+16,786,713
New +$422M 79.82% 1

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ATP Life Science Ventures's STOK Position: Q2 2021 in Review

ATP Life Science Ventures sold out of Stoke Therapeutics (STOK) in Q2 2021, closing a stake of 17,161,713 shares — an estimated $667M sold.

ATP Life Science Ventures first reported a position in STOK in Q4 2019 and held it in 6 quarters. The position peaked at $1.06B in Q4 2020. 97 funds tracked by Wall St. Rank hold STOK as of Q2 2021.

  • ATP Life Science Ventures reported no remaining Stoke Therapeutics position as of Q2 2021 after selling out during the quarter.
  • ATP Life Science Ventures sold 17,161,713 Stoke Therapeutics shares in Q2 2021, an estimated $667M.
  • ATP Life Science Ventures first reported a position in Stoke Therapeutics in Q4 2019 and held it in 6 quarters.
  • ATP Life Science Ventures's Stoke Therapeutics position peaked at $1.06B in Q4 2020.
  • 97 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2021.

Based on ATP Life Science Ventures's 13F filing for Q2 2021.